Products for Research Use Only

Cutamesine

CAT: 0804-HY-14813-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14813-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cutamesine (SA4503) is a potent and selective sigma 1 receptor agonist with an IC50 of 17.4 nM in guinea pig brain membranes. Cutamesine shows >100-fold less affinity for the sigma 2 receptor (IC50 of 1784 nM) . Cutamesine has antidepressant effects[1][2].
CAS Number
165377-43-5
Product Name Alternative
SA4503; AGY 94806
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Sigma Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/sa4503.html
Purity
99.18
Solubility
10 mM in DMSO
Smiles
COC1=CC=C(CCN2CCN(CCCC3=CC=CC=C3)CC2)C=C1OC
Molecular Formula
C23H32N2O2
Molecular Weight
368.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Lever JR, et al. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006 May;59 (6) :350-8. |[2]Ono Y, et al. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett. 2014 Jan 24;559:174-8.|[3]Minabe Y, et al. Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse. 1999 Aug;33 (2) :129-40.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Sigma 1 Receptor; Sigma 2 Receptor
Citation 01
Cell Death Dis. 2025 Jul 2;16 (1) :485.|Eur J Pharmacol. 2023 May 5:946:175647.|Mol Neurobiol. 2025 Nov 24;63 (1) :163.|Neural Regen Res. 2024 Apr 3.|Neurochem Int. 2025 Jan 28:105937.|Mol Neurobiol. 2025 Jun 1.|Pharmaceuticals (Basel) . 2025 Mar 24;18 (4) :455.